Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
- 试验地点
- 21
- 主要终点
- Hematologic and MRD response after induction therapy
研究概览
简要总结
The trial proposed here attempts to reduce induction chemotherapy to phase I of standard induction in patients with B-precursor ALL. Induction phase II will be replaced by blinatumomab.
The initial treatment phase is followed by sequential chemotherapy and further blinatumomab cycles.
详细描述
Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against CD19 expressing cells. In Phase II-III clinical trials 43-69 % of the patients treated with blinatumomab in relapsed/refractory ALL with poor prognostic features, achieved a complete hematologic remission and around 80 % of these obtained a molecular remission as well. Blinatumomab thus has demonstrated significant antileukemic activity in relapsed/refractory adult ALL. The ultimate goal for optimised management of adult ALL is to integrate targeted compounds with known single-drug activity into first-line treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 56 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with newly diagnosed CD19 positive B-precursor ALL
- •Greater than 25 % blasts in bone marrow
- •Eastern Cooperative Oncology Group (ECOG) performance status <= 2
- •Charlson comorbidity score <= 2
- •Age > 55 and < 75 years at the time of informed consent
- •Renal and hepatic function as defined below:
- •AST (SGOT), ALT(SGPT) and AP < 5x upper limit of normal (UNL) (unless related to leukemic liver infiltration by investigator assessment)
- •Total bilirubin < 1.5x ULN (unless related to Gilbert's Meulengracht disease)
- •Creatinine < 1.5x ULN
- •Creatinine clearance >= 50 mL/min (e.g. calculated according Cockroft & Gault)
- •Negative pregnancy test in women of childbearing potential
- •Ability to understand and willingness to sign a written informed consent
- •For Germany: Participation in the registry of the German Multicenter Study Group for Adult ALL (GMALL)
排除标准
- •Antileukemic pretreatment (GMALL prephase with dexamethasone and cyclophosphamide allowed)
- •History of malignancy other than ALL within 5 years prior to start of protocol-specified therapy with the exception of:
- •Malignancy treated with curative intent and with no known active disease present for 2 years before enrollment and felt to be at low risk for recurrence by the treating physician including
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated cervical carcinoma in situ without evidence of disease
- •Adequately treated breast ductal carcinoma in situ without evidence of disease
- •Prostatic intraepithelial neoplasia without evidence of prostate cancer
- •History or presence of clinically relevant (per investigator's assessment) CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome or psychosis
- •Active ALL in the CNS confirmed by CSF analysis) or testes (clinical diagnosis) or other extramedullary involvement; non-bulky lymph node (< 7.5 cm diameter) involvement will be accepted
- •Current autoimmune disease or history of autoimmune disease with potential CNS involvement
- •Known exclusion criteria to recommended chemotherapy
- •Known positivity of HIV, hepatitis B (HbsAG) or hepatitis C virus (anti-HCV)
- •Subject received prior anti-CD19 therapy
- •Live vaccination within 2 weeks before the start of study treatment
- •Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation:
- •Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing
- •Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study(s). Thirty days is calculated from day 1 of protocol-specified therapy
- •Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge
- •History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety of interfere with the study evaluation, procedures or completion
- •Woman of childbearing potential and is not willing to use a highly effective method of contraception while receiving study treatment and for an additional 3 months after the last dose of study treatment
- •Male who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception while receiving protocol-specified therapy and for at least an additional 3 months after the last dose of protocol-specified therapy.
研究组 & 干预措施
Blinatumomab
Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.
In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day.
干预措施: Blinatumomab (Drug)
结局指标
主要结局
Hematologic and MRD response after induction therapy
时间窗: after induction therapy (up to 8 weeks)
Proportion of patients achieving a complete hematologic remission and a complete molecular remission (MRD response or complete MRD response) after induction therapy defined as one cycle of chemotherapy and one cycle of blinatumomab
次要结局
- Treatment deviation 1(until end of treatment (up to 39 weeks))
- Treatment deviation 5(until end of treatment (up to 39 weeks))
- Overall Survival(1 year after start of therapy)
- Adverse Events(continuously until end-of-core-study (week 43))
- MRD response after induction and consolidation(after induction and consolidation (up to 35 weeks))
- Time to MRD relapse(continuously until end of maintenance therapy (up to 27 months))
- Relapse localisation(In case of relapse, continuously until end of maintenance therapy (up to 27 months))
- Treatment deviation 2(until end of treatment (up to 39 weeks))
- Treatment deviation 3(until end of treatment (up to 39 weeks))
- Treatment deviation 4(until end of treatment (up to 39 weeks))
- Continuous complete remission(1 year after start of therapy)
- Relapse free survival(1 year after start of therapy)
- Quality of life(until end of maintenance therapy (up to 27 months))
- Event-free survival(1 year after start of therapy)
研究者
Nicola Goekbuget
MD
Goethe University